Polifarma İlaç San

What Polifarma İlaç San does

Polifarma İlaç San. ve Tic. A.Ş. is a privately-held Turkish pharmaceutical manufacturer founded in 1986 and headquartered in Istanbul (Halkalı), with production operations in Tekirdağ and a regulatory/market access office in Ankara. The company employs between 1,001 and 5,000 people and operates an integrated manufacturing model spanning active pharmaceutical ingredient (API) synthesis through finished dosage form (FDF) production. Its product portfolio addresses multiple therapeutic areas and is exported to over 50 countries, positioning it among the top 10 Turkish pharmaceutical exporters per İKMİB rankings and a recurring presence on the Fortune 500 Turkey, ISO 500, and Capital 500 lists.

The company's R&D infrastructure is centered on its POL AR-GE facility, which supports proprietary molecule development. Its most strategically significant pipeline asset is Nusinersen, an SMA (Spinal Muscular Atrophy) treatment developed over 7 years, which is now advancing through clinical research under a 2025 collaboration protocol with TÜSEB (Türkiye Sağlık Enstitüleri Başkanlığı). Regulatory credentials include GMP certification and inclusion in the Ministry of Trade's TURQUALITY Support Program for international brand development. In 2024, the company opened an R&D Raw Material and Drug Production Center and rose 57 positions to 76th in the Turkishtime R&D Expenditure Top 500 across all sectors.

Polifarma's revenue model is built on B2B pharmaceutical product sales through domestic wholesale networks and direct export relationships, with quote-based pricing that is not publicly disclosed. Distribution is split between Turkish pharmaceutical channels and international direct-sales relationships, supported by regular participation at CPHI Frankfurt, CPHI China, CPHI India, CPHI South East Asia, and WHX Cape Town exhibitions. Leadership includes CEO Dr. Ecz. Başbuğ Öke (appointed with international strategy and export experience), Vice Chairman Vildan Kumrulu (recognized in Fortune Turkey's 50 Most Powerful Women list), and founder/Chairman Necdet Nuri Kumrulu. The company is also rolling out a QR-coded Electronic Patient Information Leaflet (e-KT) system from April 2026 to replace paper instructions.

Name

Polifarma İlaç San

Legal name

Polifarma İlaç San. ve Tic. A.Ş.

Website

https://polifarma.com.tr

Company type

Private

Founded year

1986

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Polifarma İlaç San. ve Tic. A.Ş. is a Turkish pharmaceutical manufacturer with integrated API-to-finished dosage form production, exporting to 50+ countries and developing proprietary treatments including Nusinersen for SMA disease.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

High-Potency API (HPAPI) Development & Manufacturing (HLAGAHAC), Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF), Clinical Trial Pharmacy & IMP Management at Site (HLAGACAK)

Keywords

• Pharmaceutical manufacturing
• Active pharmaceutical ingredients
• Finished dosage forms
• Proprietary drug development
• Pharmaceutical exports

Headquarters

HQ city

Halkali

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from manufacturing and selling pharmaceutical products including both API and finished dosage forms across multiple therapeutic areas. The company exports to 50+ countries and serves domestic and international markets.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Polifarma İlaç San is a Turkish pharmaceutical manufacturer that produces Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs) through integrated end-to-end manufacturing. The company operates an in-house R&D center (POL AR-GE) for proprietary molecule development, including the locally developed Nusinersen SMA treatment, and exports pharmaceutical products to more than 50 countries.

Product overview

Polifarma İlaç San is a Turkish pharmaceutical company with integrated manufacturing capabilities spanning active pharmaceutical ingredient (API) synthesis to finished dosage forms (FDF). The company operates a comprehensive product portfolio including the locally-developed Nusinersen treatment for SMA, supported by its POL AR-GE R&D center. Polifarma exports to over 50 countries and maintains production facilities in Turkey.

Differentiator

Problem solved

Functional benefit

Products and services

• Polifarma Pharmaceutical Product Portfolio Comprehensive portfolio of pharmaceutical products including active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs) across multiple therapeutic areas, manufactured at the Tekirdağ production facility and distributed domestically and internationally to healthcare providers, pharmacies, and pharmaceutical distributors.
• Nusinersen (SMA Treatment) Locally developed Nusinersen active substance and drug for the treatment of Spinal Muscular Atrophy (SMA), developed over 7 years by Polifarma and entering clinical research collaboration with TÜSEB. Targeted at healthcare providers treating rare disease patients.

Quantifiable outcome

• Ranked 76th among all sectors in R&D spending - Turkishtime 2024 ranking, up 57 positions from previous year
• +2 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• TÜSEB (Türkiye Sağlık Enstitüleri Başkanlığı)coreStrategic or Co-development Partner · 1 November 2024Clinical research collaboration protocol signed between Polifarma and TÜSEB for SMA disease local drug active substance and drug production project clinical trials. The 7-year developed Nusinersen product was showcased as an example in TÜSEB's 'Üreten Sağlık' project during the 11th Turkish Medical World Congress.
• T.C. Ticaret BakanlığıcoreOthersPolifarma included in TURQUALITY Support Program, which provides support for international branding and sustainable growth for Turkish brands.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Abdi İbrahim: Turkey's largest pharmaceutical company, manufacturing branded and generic products with integrated capabilities and significant export operations. Closest direct comparable to Polifarma in scale, therapeutic breadth, and integrated manufacturing footprint.
• Eczacıbaşı İlaç (Eczacıbaşı Pharmaceuticals): Major Turkish pharma manufacturer with branded generics, OTC, and hospital specialty products. Comparable to Polifarma across domestic manufacturing, broad therapeutic portfolio, and export-driven growth.
• Nobel İlaç: Turkish pharmaceutical manufacturer with integrated API and FDF capabilities and a strong export orientation. Closely comparable to Polifarma on integrated manufacturing and international market presence.
• Deva Holding: Turkish pharma company producing branded generics, APIs, and finished dosage forms with global export operations. Comparable to Polifarma across product mix, API integration, and emerging-market focus.
• İlko İlaç: Turkish pharmaceutical manufacturer focused on generics with growing export presence. Comparable to Polifarma on FDF manufacturing and emerging-market distribution strategy.
• Ali Raif İlaç: Established Turkish pharmaceutical manufacturer with broad generic and branded portfolio. Comparable to Polifarma on domestic manufacturing scale and mid-cap pharma positioning.

Broad incumbents

• Sandoz (Turkey / global): Global leader in generic pharmaceuticals and APIs with extensive emerging-market presence. Comparable to Polifarma as a much larger incumbent competing in the same generic and API export markets.
• Biogen: Originator of Spinraza (Nusinersen) for SMA. Directly relevant peer for Polifarma's Nusinersen development program as the comparator/innovator whose market Polifarma would contest if it launches domestically.
• Aurobindo Pharma: Large Indian generic and API manufacturer with global distribution. Comparable to Polifarma as a low-cost API/FDF competitor active in the same emerging-market tender channels.

Others

• TÜSEB (Türkiye Sağlık Enstitüleri Başkanlığı): Turkish Health Institutes Presidency, Polifarma's clinical research collaboration partner on the SMA Nusinersen program. Relevant as a strategic ecosystem counterparty rather than a commercial peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Polifarma_Serum
• LinkedInlinkedin.com/company/polifarma-ilac

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Polifarma İlaç San